- Home
- INVE vs CGTX Comparison
INVE vs CGTX Comparison
Compare INVE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | CGTX |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 94.5M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INVE | CGTX |
|---|---|---|
| Price | $3.72 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.50 | $3.33 |
| AVG Volume (30 Days) | 120.7K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.00 | $0.22 |
| 52 Week High | $4.08 | $3.83 |
Technical Indicators
Market Signals| Indicator | INVE | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 57.26 |
| Support Level | $3.18 | $1.01 |
| Resistance Level | $3.85 | $1.19 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 64.71 | 93.96 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.